Volume 14, Issue 8 (8-2016)                   IJRM 2016, 14(8): 507-510 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Eftekhar M, Miraj S, Mortazavifar Z. The effect of luteal phase gonadotropin-releasing hormone antagonist administration on IVF outcomes in women at risk of OHSS. IJRM 2016; 14 (8) :507-510
URL: http://ijrm.ir/article-1-777-en.html
The effect of luteal phase gonadotropin-releasing hormone antagonist administration on IVF outcomes in women at risk of OHSS
Maryam Eftekhar1 , Sepideh Miraj * 2, Zahrasadat Mortazavifar1
1- Research and Clinical Center for Infertility, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2- Research and Clinical Center for Infertility, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran , dr.s.miraj@gmail.com
Abstract:   (3180 Views)
Background: Gonadotropin-releasing hormone (GnRH) plays essential roles in embryo implantation, invasion of trophoblastic tissue, and steroid synthesis in the placenta.
Objective: The aim of this study was to evaluate the effect of GnRH antagonist administration on pregnancy outcomes in early implantation period.
Materials and Methods: In this retrospective study, 94 infertile women undergoing GnRH antagonist protocol who were at risk of ovarian hyperstimulation syndrome (OHSS) were included. Sixty-seven patients (group I) received Cetrorelix 0.25 mg/daily in the luteal phase for 3 days while in 27 participants (group II), it was not administered. Pregnancy outcomes were assessed based on chemical and clinical pregnancy rates.
Results: The pregnancy outcomes were not significantly different between two groups (p=0.224).
Conclusion: The present study proposed that luteal phase GnRH antagonist administration does not influence the chance of successful pregnancy outcomes.
Keywords: Gonadotropin-releasing hormone antagonist, Pregnancy outcome, In vitro fertilization.
Full-Text [PDF 93 kb]   (807 Downloads) |   |   Full-Text (HTML)  (321 Views)  
Type of Study: Original Article |
References
1. Lainas GT, Kolibianakis EM, Sfontouris IA, Zorzovilis IZ, Petsas GK, Tarlatzi TB, et al. Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study. Reprod Biol Endocrinol 2012; 10: 69-71. [DOI:10.1186/1477-7827-10-69]
2. Lainas G, Kolibianakis E, Sfontouris I, Zorzovilis I, Petsas G, Lainas T, et al. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS. Hum Reprod 2013; 28: 1929-1942. [DOI:10.1093/humrep/det114]
3. Lainas T, Sfontouris I, Zorzovilis I, Petsas G, Lainas G, Kolibianakis E. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist. Reprod Biomed Online 2007; 15: 408-412. [DOI:10.1016/S1472-6483(10)60366-5]
4. Lainas TG, Sfontouris I, Zorzovilis I, Petsas G, Lainas G, Iliadis G, et al. Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol. Reprod Biomed Online 2009; 18: 15-20. [DOI:10.1016/S1472-6483(10)60419-1]
5. Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod 2002; 17: 874-885. [DOI:10.1093/humrep/17.4.874]
6. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008; 89: 84-91. [DOI:10.1016/j.fertnstert.2007.02.002]
7. Klemmt PAB, Liu F, Carver JG, Jones C, Brosi D, Adamson J, et al. Effects of gonadotrophin releasing hormone analogues on human endometrial stromal cells and embryo invasion in vitro. Hum Reprod 2009; 24: 2187-2192. [DOI:10.1093/humrep/dep181]
8. Lainas TG, Sfontouris I, Zorzovilis I, Petsas G, Lainas G, Alexopoulou E, et al. Live births after management of severe OHSS by GnRH antagonist administration in the luteal phase. Reprod Biomed Online 2009; 19: 789-795. [DOI:10.1016/j.rbmo.2009.09.021]
9. Olivennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J, Frydman R. The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Hum Reprod 1998; 13: 2411-2414. [DOI:10.1093/humrep/13.9.2411]
10. Boerrigter PJ, de Bie JJ, Mannaerts BMJL, van Leeuwen BP, Passier-Timmermans DPJ. Obstetrical and neonatal outcome after controlled ovarian stimulation for IVF using the GnRH antagonist ganirelix. Hum Reprod 2002; 17: 2027-2034. [DOI:10.1093/humrep/17.8.2027]
11. Bosch E, Valencia I, Escudero E, Crespo J, Simón C, Remohí J, et al. Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertil Steril 2003; 80: 1444-1449. [DOI:10.1016/j.fertnstert.2003.07.002]
12. Pellicer A, Albert C, Mercader A, Bonilla-Musoles F, Remohí J, Simón C. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1β, interleukin-6, and vascular endothelial growth factor. Fertil Steril 1999; 71: 482-489. [DOI:10.1016/S0015-0282(98)00484-1]
13. Gómez R, Soares SR, Busso C, Garcia-Velasco JA, Simón C, Pellicer A, editors. Physiology and pathology of ovarian hyperstimulation syndrome. Semin Reprod Med 2010; 28: 448-457. [DOI:10.1055/s-0030-1265670]
14. Rizk B, Aboulghar M, Smitz J, Ron-El R. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update 1997; 3: 255-266. [DOI:10.1093/humupd/3.3.255]
15. Soares SR, Gómez R, Simón C, García-Velasco JA, Pellicer A. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update 2008; 14: 321-333. [DOI:10.1093/humupd/dmn008]
16. Eftekhar M, Firouzabadi RD, Karimi H, Rahmani E. Outcome of cryopreserved-thawed embryo transfer in the GnRH agonist versus antagonist protocol. Iran J Reprod Med 2012; 10: 297.
17. Bonduelle M, Oberyé J, Mannaerts B, Devroey P. Large prospective, pregnancy and infant follow-up trial assures the health of 1000 fetuses conceived after treatment with the GnRH antagonist ganirelix during controlled ovarian stimulation. Hum Reprod 2010; 25: 1433-1440. [DOI:10.1093/humrep/deq072]
18. Bonilla-Musoles F, Raga F, Castillo J, Sanz M, Dolz M, Osborne N. High doses of GnRH antagonists are efficient in the management of severe ovarian hyperstimulation syndrome. Clin Exp Obstet Gynecol 2008; 36: 78-81.
19. Siler-Khodr T, Khodr G, Rhode J, Vickery B, Nestor J. Gestational age-related inhibition of placental hCG, αchCG and steroid hormone release in vitro by a GnRH antagonist. Placenta 1987; 8: 1-14. [DOI:10.1016/0143-4004(87)90035-X]
20. Ubaldi F, Camus M, Smitz J, Bennink HC, Van Steirteghem A, Devroey P. Premature luteinization in in vitro fertilization cycles using gonadotropinreleasing hormone agonist (GnRH-a) and recombinant follicle-stimulating hormone (FSH) and GnRH-a and urinary FSH. Fertil Steril 1996; 66: 275-280. [DOI:10.1016/S0015-0282(16)58453-2]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb